# Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

> **NCT03207945** · PHASE3 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 118 (actual)

## Conditions studied

- Dyslipidemias
- Cardiovascular Diseases
- HIV Infections

## Interventions

- **DRUG:** Alirocumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03207945
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-30
- **Primary completion:** 2025-08-24
- **Final completion:** 2025-09-24
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207945, "Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03207945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*